Looking to enhance your portfolio with high-growth, financially-robust stocks, but not sure where you should even begin? Stocks such as Knight Therapeutics and Callidus Capital are deemed to be superior in terms of how much they’re expected to earn and return to shareholders, according to analysts. I would suggest taking a look at my list of companies that compare favourably in all criteria, and consider whether they would add value to your current portfolio.
Knight Therapeutics Inc. (TSX:GUD)
Knight Therapeutics Inc., a specialty pharmaceutical company, engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada and internationally. The company currently employs 27 people and with the company’s market capitalisation at CAD CA$1.10B, we can put it in the small-cap group.
GUD’s forecasted bottom line growth is an optimistic 13.80%, driven by the underlying double-digit sales growth of 47.73% over the next few years. It appears that GUD’s profitability may be sustainable as the fundamental push is top-line expansion rather than unmaintainable cost-cutting activities. This prospective profitability should trickle down to shareholders, with analysts expecting the company to generate a positive return on equity of 2.41%. GUD ticks the boxes for robust growth generation on all levels of line items, which makes it an appealing stock to dig into deeper. Thinking of investing in GUD? Have a browse through its key fundamentals here.
Callidus Capital Corporation (TSX:CBL)
Callidus Capital Corporation operates as a specialty asset based lender in Canada and the United States. Started in 2003, and currently run by Newton Glassman, the company size now stands at 35 people and with the company’s market cap sitting at CAD CA$460.98M, it falls under the small-cap stocks category.
Interested to learn more about CBL? Other fundamental factors you should also consider can be found here.
Aeterna Zentaris Inc. (TSX:AEZS)
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health. Established in 1991, and headed by CEO Michael Ward, the company currently employs 56 people and with the company’s market capitalisation at CAD CA$38.80M, we can put it in the small-cap category.
AEZS’s forecasted bottom line growth is an optimistic double-digit 36.84%, driven by underlying sales, which is expected to more than double, over the next few years. An affirming signal is when net income increase is supported by top-line growth. Since net income isn’t artificially inflated by one-off initiatives such as cost-cutting, we know this profit growth is more likely to be sustainable. AEZS’s bullish prospects on both the top and bottom lines make it an interesting stock to invest more time to understand how it can add value to your portfolio. A potential addition to your portfolio? Have a browse through its key fundamentals here.
For more financially robust companies with high growth potential to enhance your portfolio, use our free platform to explore our interactive list of these stocks.
To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.
The author is an independent contributor and at the time of publication had no position in the stocks mentioned.